ENA-001
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 15, 2024 (NCT06137638)
Timeline
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCCNc1nc(NCCC)nc(N(C)OC)n1- Mol. weight
- 254.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068510 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06967259 | Phase 1 | May 14, 2025 | Enalare Therapeutics Inc., National Institute on Drug Abuse (NIDA) |
| NCT06137638 | Phase 2 | Mar 15, 2024 | Nema Research |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enalare Therapeutics Inc. | For profit | 1 | 1 | 1 | 2025 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2025 |
| Nema Research | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1